These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37654488)

  • 1. Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination.
    Yin D; Han Z; Lang B; Li Y; Mai G; Chen H; Feng L; Chen YQ; Luo H; Xiong Y; Jing L; Du X; Shu Y; Sun C
    Front Immunol; 2023; 14():1195533. PubMed ID: 37654488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are higher antibody levels against seasonal human coronaviruses associated with a more robust humoral immune response after SARS-CoV-2 vaccination?
    Asamoah-Boaheng M; Grunau B; Karim ME; Jassem AN; Bolster J; Marquez AC; Scheuermeyer FX; Goldfarb DM
    Front Immunol; 2022; 13():954093. PubMed ID: 36159791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization.
    Wang J; Guo C; Cai L; Liao C; Yi H; Li Q; Hu H; Deng Q; Lu Y; Guo Z; Chen Z; Lu J
    Front Immunol; 2021; 12():772511. PubMed ID: 34868035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination.
    Hu C; Wang Z; Ren L; Hao Y; Zhu M; Jiang H; Wang S; Li D; Shao Y
    Front Cell Infect Microbiol; 2022; 12():978440. PubMed ID: 36118022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2.
    Galipeau Y; Siragam V; Laroche G; Marion E; Greig M; McGuinty M; Booth RA; Durocher Y; Cuperlovic-Culf M; Bennett SAL; Crawley AM; Giguère PM; Cooper C; Langlois MA
    EBioMedicine; 2021 Dec; 74():103700. PubMed ID: 34861490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
    Woudenberg T; Pelleau S; Anna F; Attia M; Donnadieu F; Gravet A; Lohmann C; Seraphin H; Guiheneuf R; Delamare C; Stefic K; Marlet J; Brochot E; Castelain S; Augereau O; Sibilia J; Dubos F; Meddour D; Guen CG; Coste-Burel M; Imbert-Marcille BM; Chauvire-Drouard A; Schweitzer C; Gatin A; Lomazzi S; Joulié A; Haas H; Cantais A; Bertholon F; Chinazzo-Vigouroux MF; Abdallah MS; Arowas L; Charneau P; Hoen B; Demeret C; Werf SV; Fontanet A; White M
    EBioMedicine; 2021 Aug; 70():103495. PubMed ID: 34304047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.
    Amanat F; Clark J; Carreño JM; Strohmeier S; Yellin T; Meade PS; Bhavsar D; Muramatsu H; Sun W; Coughlan L; Pardi N; Krammer F
    J Virol; 2023 Mar; 97(3):e0166422. PubMed ID: 36779758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.
    Wratil PR; Schmacke NA; Karakoc B; Dulovic A; Junker D; Becker M; Rothbauer U; Osterman A; Spaeth PM; Ruhle A; Gapp M; Schneider S; Muenchhoff M; Hellmuth JC; Scherer C; Mayerle J; Reincke M; Behr J; Kääb S; Zwissler B; von Bergwelt-Baildon M; Eberle J; Kaderali L; Schneiderhan-Marra N; Hornung V; Keppler OT
    Cell Rep; 2021 Dec; 37(13):110169. PubMed ID: 34932974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced seasonal coronavirus incidence in high-risk population groups during the COVID-19 pandemic.
    Heiskanen A; Galipeau Y; Little J; Langlois MA; Cooper CL
    Immun Inflamm Dis; 2024 Jul; 12(7):e1342. PubMed ID: 39023424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
    Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
    Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
    Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
    Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incomplete IgG avidity maturation after seasonal coronavirus infections.
    Struck F; Schreiner P; Staschik E; Wochinz-Richter K; Schulz S; Soutschek E; Motz M; Bauer G
    J Med Virol; 2022 Jan; 94(1):186-196. PubMed ID: 34427932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
    Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
    Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
    Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses.
    Spatola M; Nziza N; Jung W; Deng Y; Yuan D; Dinoto A; Bozzetti S; Chiodega V; Ferrari S; Lauffenburger DA; Mariotto S; Alter G
    Brain; 2023 Oct; 146(10):4292-4305. PubMed ID: 37161609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.